Lenvatinib-Associated Fulminant Type 1 Diabetes Mellitus

Am J Ther. 2023 Nov-Dec;30(6):e561-e563. doi: 10.1097/MJT.0000000000001495. Epub 2022 Mar 24.

Authors

Pei-Fei Liao¹, Tzu-Rong Peng¹, Ta-Wei Wu¹, Ya-Hui Hu²

Affiliations

¹ Department of Pharmacy, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan, China.
² Division of Endocrinology and Metabolism, Department of Internal Medicine, Taipei Tzu-Chi Hospital, Buddhist Tzu-Chi Medical Foundation, New Taipei City, Taiwan, China.

PMID: 37921683
DOI: 10.1097/MJT.0000000000001495

No abstract available

Publication types

Letter

MeSH terms

Diabetes Mellitus, Type 1* / chemically induced
Diabetes Mellitus, Type 1* / drug therapy
Diabetic Ketoacidosis*
Humans
Phenylurea Compounds / adverse effects
Quinolines* / adverse effects

Substances

lenvatinib
Phenylurea Compounds
Quinolines